July 29, 2019 / 5:09 AM / 21 days ago

BRIEF-Novartis Gives Update On Phase III PARAGON-HF Trial In Heart Failure Patients

July 29 (Reuters) - Novartis Ag:

* NOVARTIS PROVIDES UPDATE ON PHASE III PARAGON-HF TRIAL IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION (HFPEF)

* PARAGON STUDY NARROWLY MISSES STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT; OVERALL SAFETY PROFILE CONFIRMED

* TOTALITY OF EVIDENCE SUGGESTS POTENTIAL CLINICALLY IMPORTANT BENEFIT; RESULTS WILL BE PRESENTED IN SEPTEMBER AT ESC CONGRESS 2019 Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below